RXi Pharmaceuticals Announces Investor and Analyst Symposium

  RXi Pharmaceuticals Announces Investor and Analyst Symposium

Business Wire

WESTBOROUGH, Mass. -- April 29, 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
that it will hold its first Investor and Analyst Symposium.

During this meeting, the company Management and members of its Scientific
Advisory Board will provide more details on RXi’s current clinical development
compound for the treatmentof dermal scarring, RXI-109, as well as insights
into the company's other research programs and their potential.
"Asmentionedon several occasions, RXi Pharmaceuticals will have the complete
unblinded data of theirtwo Phase 1 studies available around the middle of
this year", said Dr. Geert Cauwenbergh, President and CEO of the Company. He
added that, "At this Investor and Analyst Symposium, we expect to announce the
formal transition of RXI-109 into a Phase 2 clinical development program, and
also provide more detailon the indications and patient populationwe will
target in our Phase 2 studies. In addition the company will alsogive an
update on its other earlier stage programs, with special emphasis on the
ophthalmologic applications of its game changing self delivering RNAi
platform."

This event will be held on Friday July 12, 2013, from11:00am to 2:00pm at the
OTCQX Market Center, 304 Hudson Street, New York, NY. Registration is required
to attend this event, please contact Tamara McGrillen at
tmcgrillen@rxipharma.com or 508-929-3646. A live webcast of the presentation
will be available on the “Investors” section of the Company's website,
www.rxipharma.com. A replay of the presentation will be available for 90 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, targets connective tissue growth
factor (CTGF) to reduce dermal scarring (fibrosis), entered into human
clinical trials in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies. Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contact:

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com